NONCONTRACEPTIVE HORMONE USE AND RISK OF BREAST-CANCER

被引：63

作者：

YANG, CP ^{[1
]}

DALING, JR ^{[1
]}

BAND, PR ^{[1
]}

GALLAGHER, RP ^{[1
]}

WHITE, E ^{[1
]}

WEISS, NS ^{[1
]}

机构：

[1] BRITISH COLUMBIA CANC AGCY,DIV EPIDEMIOL BIOMETRY & OCCUPAT ONCOL,600 W 10TH AVE,VANCOUVER V5Z 4E6,BC,CANADA

来源：

CANCER CAUSES & CONTROL | 1992年 / 3卷 / 05期

关键词：

BREAST CANCER; CANADA; ESTROGENS; PROGESTERONE;

D O I：

10.1007/BF00051360

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

All British Columbia (Canada) women under 75 years of age who were diagnosed with breast cancer during 1988-89 were asked to complete a postal questionnaire which included detailed information on menopausal estrogen use. Controls were drawn from the Provincial Voters List, matched by five-year age category to the cases. The present analysis consists of 699 cases and 685 controls who were postmenopausal due to natural causes or to a hysterectomy. There was no overall increase in risk of breast cancer associated with ever-use of unopposed estrogen (odds ratio [OR] = 1.0, 95 percent confidence interval [CI] = 0.8-1.3). For estrogen use of 10 years or longer, the relative risk [RR] was 1.6 (CI = 1.1-2.5). The risk estimate for current users was somewhat elevated (OR = 1.4, CI = 1.0-2.0). Compared with women who never used hormone preparations, women who had used estrogen plus progestogen had an RR of 1.2 (CI = 0.6-2.2). Our results suggest that ever-use of estrogen, with or without progestogen, does not appreciably increase the risk of breast cancer. However, long-term and recent use of unopposed estrogen may be associated with a moderately increased risk.

引用

页码：475 / 479

页数：5

共 46 条

[1]

Casagrande J., Gerkins V., Henderson B.E., Mack T., Pike M.C., Brief communication: Exogenous estrogens and breast cancer in women with natural menopause, JNCI, 56, pp. 839-41, (1976)

[2]

Hoover R., Gray L.A., Cole P., MacMahon B., Menopausal estrogens and breast cancer, N Engl J Med, 295, pp. 401-5, (1976)

[3]

Startwell P.E., Arthes F.G., Tonascia J.A., Exogenous hormones, reproductive history and breast cancer, JNCI, 59, pp. 1589-92, (1977)

[4]

Brinton L.A., Willia R.R., Hoover R.N., Et al., Breast cancer risk factors among screening program participants, JNCI, 62, pp. 37-44, (1979)

[5]

Ross R.K., Paganini-Hill A., Gerkins V.R., Et al., A casecontrol study of menopausal estrogen therapy and breast cancer, JAMA, 243, pp. 1635-9, (1980)

[6]

Jick H., Walker A.M., Watkins R.N., Et al., Replacement estrogens and breast cancer, Am J Epidemiol, 112, pp. 586-94, (1980)

[7]

Brinton L.A., Hoover R.N., Szklo M., Et al., Menopausal estrogen use and risk of breast cancer, Cancer, 47, pp. 2517-22, (1981)

[8]

Kelsey J.L., Fisher D.B., Holford T.R., Et al., Exogenous estrogens and other factors in the epidemiology of breast cancer, JNCI, 67, pp. 327-33, (1981)

[9]

Hoover R., Glass A., Azevedo D., Milne K., Conjugated estrogens and breast cancer risk in women, JNCI, 67, pp. 815-20, (1981)

[10]

Lawson D.H., Jick H., Hunter J.R., Et al., Exogenous estrogens and breast cancer, Am J Epidemiol, 114, pp. 710-13, (1981)

← 1 2 3 4 5 →